TuisONC • NASDAQ
add
Beigene Ltd
Vorige sluiting
$271,80
Dagwisseling
$240,00 - $258,96
Jaarwisseling
$172,67 - $287,88
Markkapitalisasie
25,56 mjd USD
Gemiddelde volume
448,91 k
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,19 mjd | 84,84% |
Bedryfskoste | 1,09 mjd | 19,51% |
Netto inkomste | -139,70 m | 58,27% |
Netto winsgrens | -11,75 | 77,43% |
Wins per aandeel | -0,80 | -196,59% |
EBITDA | -33,25 m | 90,73% |
Effektiewe belastingkoers | -112,84% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,63 mjd | -17,16% |
Totale bates | 5,92 mjd | 1,99% |
Totale aanspreeklikheid | 2,59 mjd | 14,14% |
Totale ekwiteit | 3,33 mjd | — |
Uitstaande aandele | 106,72 m | — |
Prys om te bespreek | 8,71 | — |
Opbrengs op bates | -3,26% | — |
Opbrengs op kapitaal | -4,29% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -139,70 m | 58,27% |
Kontant van bedrywe | 111,61 m | 128,21% |
Kontant van beleggings | -247,31 m | 26,86% |
Kontant van finansiering | 30,05 m | -92,11% |
Netto kontantverandering | -155,64 m | 57,59% |
Beskikbare kontantvloei | 434,97 m | 505,95% |
Meer oor
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Gestig
28 Okt. 2010
Webwerf
Werknemers
11 000
